Italy - English - myHealthbox

guna - roe extract, high molecular weight hyaluronic acid, inositol, hop extract, cocoa extract, ginseng, guaranÀ,lotus extract, hydrolyzed dna and rna, maca extract, trace elements, anti-spot complex - serum - aqua/water, dimethicone, decyl oleate, glycerin, butylene glycol, dipropylene glycol, bis-peg/ppg-16/16 peg/ppg-16/16 dimethicone, saccharomyces/copper ferment, saccharomyces ferment, saccharomyces/magnesium ferment, saccharomyces/silicon ferment, saccharo - cosmetics

United States - English - NLM (National Library of Medicine)

abbvie inc. - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825), ombitasvir heminonahydrate (unii: eqe3i70j3w) (ombitasvir - unii:2302768xj8), paritaprevir dihydrate (unii: hrq5901o78) (paritaprevir - unii:ou2ym37k86) - ritonavir 50 mg - technivie is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis c virus (hcv) infection without cirrhosis or with compensated cirrhosis [see clinical studies (14)] . - the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin. - technivie is contraindicated: in patients with moderate to severe hepatic impairment (child-pugh b and c) due to risk of potential toxicity [see warnings and precautions (5.2), use in specific populations (8.6) and clinical pharmacology (12.3)] . with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events [see drug interactions (7) and clinical pharmacology (12.3)] : alpha1-adrenoreceptor antagonist: alfuzosin hcl anti-anginal: ranolazine antiarrhythmic: dronedarone anti-gout: colchicine in patients with renal and/or hepat

United States - English - NLM (National Library of Medicine)

abbvie inc. - ombitasvir heminonahydrate (unii: eqe3i70j3w) (ombitasvir - unii:2302768xj8), paritaprevir dihydrate (unii: hrq5901o78) (paritaprevir - unii:ou2ym37k86), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - ombitasvir 12.5 mg - viekira pak is indicated for the treatment of adult patients with chronic hepatitis c virus (hcv) [see dosage and administration ( 2.2 ) and clinical studies ( 14 )] : - genotype 1b without cirrhosis or with compensated cirrhosis - genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin. - if viekira pak is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin. - viekira pak is contraindicated: ○ in patients with moderate to severe hepatic impairment (child-pugh b and c) due to risk of potential toxicity [see warnings and precautions ( 5.2 ), use in specific populations ( 8.6 ) and clinical pharmacology ( 12.3 )] . ○ with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events [see drug interactions ( 7 ) and clinical pharm

United States - English - NLM (National Library of Medicine)

abbvie inc. - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825), dasabuvir sodium monohydrate (unii: og6d40m62l) (dasabuvir - unii:de54eqw8t1), paritaprevir dihydrate (unii: hrq5901o78) (paritaprevir - unii:ou2ym37k86), ombitasvir heminonahydrate (unii: eqe3i70j3w) (ombitasvir - unii:2302768xj8) - ritonavir 33.33 mg - viekira xr is indicated for the treatment of adult patients with chronic hepatitis c virus (hcv) [see dosage and administration (2.2) and clinical studies (14)] : - genotype 1b infection without cirrhosis or with compensated cirrhosis - genotype 1a infection without cirrhosis or with compensated cirrhosis for use in combination with ribavirin. - if viekira xr is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin. - viekira xr is contraindicated: in patients with moderate to severe hepatic impairment (child-pugh b and c) due to risk of potential toxicity [see warnings and precautions (5.2), use in specific populations (8.6) and clinical pharmacology (12.3)] . with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events [see drug interactions (7) and clinical pharmac

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;  ; ribavirin 400mg;  ; ribavirin 600mg - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 400mg   excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90553 povidone active: ribavirin 600mg excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90623 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;  ; ribavirin 600mg;   - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 600mg   excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90623 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.

European Union - English - EMA (European Medicines Agency)

abbvie ltd - dasabuvir sodium - hepatitis c, chronic - antivirals for systemic use, - exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults. for hepatitis c virus (hcv) genotype specific activity.,

European Union - English - EMA (European Medicines Agency)

abbvie ltd - ombitasvir / paritaprevir / ritonavir - hepatitis c, chronic - antivirals for systemic use - viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;   - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;  ; ribavirin 200mg;   - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 200mg   excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90614 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.